

Are you ordering SPEP alone to rule out monoclonal gammopathies?

You could be missing **1 out of 8** patients with Multiple Myeloma^{1,2}

SPEP + FLC + IFE

Provides >99% diagnostic sensitivity in detection of Multiple Myeloma¹⁻³.



Multiple Myeloma Diagnostic Algorithm	% Diagnostic Sensitivity
SPEP alone	88
Freelite® (FLC*) tests alone	97
SPEP, Freelite tests +/- IFE**	>99

Freelite tests measure free kappa and free lambda light chains including at concentrations below what SPEP can detect⁴⁻⁶

With SPEP alone >12% of patients with myeloma will be missed^{1,2}

Timely diagnosis of myeloma helps reduce severe secondary complications such as spinal fractures and advanced renal impairment⁷

*FLC = Free Light Chains | **IFE = Immunofixation Electrophoresis

Guidelines - Aid in Diagnosis: ⁸⁻¹⁰

Recommendation	Guideline
"the serum FLC assay [test] in combination with serum protein electrophoresis [SPEP] and immunofixation [IFE] yields high sensitivity, and negates the need for 24-hour urine studies for diagnoses other than light chain amyloidosis (AL)."	IMWG International Myeloma Working Group
"Use of serum free light chain (FLC) assay [tests] along with SPEP and sIFE yields high sensitivity while screening for Multiple Myeloma and related plasma cell disorders"	NCCN National Comprehensive Cancer Network
"Clinical care providers should order both SPEP and sFLC for the initial detection of M protein in all patients with suspected Monoclonal Gammopathies." - Strong Recommendation	CAP College of American Pathologists

Guidelines recommend Freelite tests alongside SPEP and IFE to gain greater diagnostic sensitivity⁸⁻¹⁰.

Freelite Test Results¹¹:

Freelite tests provide three values:

a concentration of free kappa light chains and free lambda light chains, as well as a kappa/lambda ratio.

An abnormal kappa/lambda ratio is a sensitive marker of plasma cell clonality.

Serum Free Light Chain Tests Reference Range

Normal Adult Serum	95 Percentile Range
Free Kappa	3.30-19.40 (mg/L)
Free Lambda	5.71-26.30 (mg/L)

Ratio <0.26	0.26-1.65	Ratio >1.65
Abnormal Ratio	Normal Ratio	Abnormal Ratio

Testing is available at:

Testing is available at:	Test Name	Test Code:

CPT Codes¹²:

83521 (x2)

Free Light Chain Kappa and Lambda (FLC)

84165

Serum Protein Electrophoresis (SPEP)

86334

Serum Immunofixation Electrophoresis (sIFE)

References

1. Abraham RS et al. Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma. Clin Chem 2002; 48:655-7.
2. Bradwell AR et al. Serum test for assessment of patients with Bence Jones myeloma. The Lancet 2003;361:489-91.
3. Katzmman JA et al. Screening Panels for Detection of Monoclonal Gammopathies. Clin Chem 2009;55:1517-22
4. Keren DF et al. Laboratory evaluation for monoclonal gammopathies: MGUS to myeloma. Warde Report 2010;21.
5. Bakshi NA et al. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins. Am J Clin Pathol 2005;124:214-8
6. Hill PG et al. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 2006;52:1743-8
7. Greipp PR et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20
8. Dispenzieri A et al. International Myeloma Working Group Guidelines for serum free light chains in multiple myeloma and other related disorders, Leukemia 2009;23:215
9. Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology® for Multiple Myeloma 2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed January 2023. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
10. Keren DF et al. Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology. Arch Pathol Lab Med 2021;146:575-90
11. Optilite® Freelite® Kappa Free Kit INS016.OPT.A & Optilite® Freelite® Lambda Free Kit INS018.OPT.A, Version: 17th June 2015
12. Clinical Laboratory Fee Schedule Files | CMS

Contact us: www.us.bindingsite.com

Freelite® is registered trademark of The Binding Site Group Ltd. (Birmingham, UK) in certain countries.

© 2023, The Binding Site, part of Thermo Fisher Scientific